![]() ![]() Finally, in 2015 as employee number two in GSK’s new Oncology Cell Therapy R&D unit, I helped build the unit and drive its strategy and partnerships. Next, I moved to Sydney, Australia, to gain experience in the clinical and regulatory side. In 2013, I was 1 of 12 successful candidates from over 1,200 applicants to join GSK’s flagship ‘Esprit R&D’ talent development program, a global, rotational program which challenges participants to develop a breadth by taking on stretch goals in new fields of research or disciplines within GSK’s R&D organization.ĭuring my first rotation on the program, I led a small molecule-based regenerative medicine program in cartilage repair in Philadelphia, my first foray into small molecule drug discovery. My time at Pfizer brought an opportunity to move from the UK to La Jolla, California, where I led several vaccine research programs for HIV, influenza, and streptococcus. I subsequently obtained my D.Phil in HIV Vaccine Research from the University of Oxford before joining Pfizer’s Vaccine Research organization in 2007. Walk us through your background from College through Industry to what you’re doing now.Īs a first-generation college student, I obtained my Bachelor’s degree in Immunology with Study in Industry from the University of Bristol (UK) in 2002, spending my industry year at GlaxoSmithKline. In 2019 Neil returned to academia to take up a role at the UPenn Center for Cellular Immunotherapies. Since 2015, Neil has focused exclusively on CAR and TCR therapy for cancer, during which time he has led multidisciplinary teams and taken assets into the clinic at GSK and Tmunity. Neil’s expertise draws on time in the UK, Australia, and both the East & West Coasts of the USA. He has over 18 years’ experience in the fields of vaccines and immunotherapies, including over a dozen years leading drug discovery and development programs in Big Pharma and Biotech. Neil Sheppard is an Immunologist educated in the UK at the Universities of Bristol and Oxford. This edition features 5 Questions with Neil Sheppard, Immunologist, University of Pennsylvania. “5 Questions With…” is a weekly BioBuzz series where we reach out to interesting people in the BioHealth Capital Region to share a little about themselves, their work, and maybe something completely unrelated. You will have the opportunity not only to learn and move forward but also to make your mark.5 Questions with Neil Sheppard, Immunologist, University of Pennsylvania Working at Roche means working at the forefront of innovation. Our Gene Therapy Development Center south of Munich will be the core element and nucleus of this work."Ĭross-functional collaborations, empowerment, and our learning culture help us to get better every day and fulfill our purpose: “Doing now what patients need next." We are deeply committed to go beyond the current state of the art, and beyond what we think is possible for developing and manufacturing gene therapies. Markus Haindl, who heads the new PTC Gene Therapy unit, explains, "In order to make these new therapies available to patients worldwide, we need to think in new paradigms. To address these challenges, Roche recently formed a new organization focusing on end-to-end CMC (Chemistry, Manufacturing & Controls) development and manufacturing of cell and gene therapies: Pharma Technical Cell & Gene Therapy (PTC). But how are these advances in the lab translated into therapies for patients? With cell therapy, cells may be modified to prompt an immune response to a specific tumor, for example, once introduced to a patient. With gene therapy, genetic code that is responsible for a disease is removed, modified, or replaced. ![]()
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |